Loading
A phase 2/3 trial of nimotuzumab in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.
Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer is a phase 2/3, randomised interventional study registered as NCT06409429 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 146 participants, started 2024-05-01 and due to reach its primary completion in 2027-05-30. Interventions recorded: Nimotuzumab; GX; Placebo. Conditions listed: Pancreatic Cancer. Primary outcome: relapse-free survival (RFS). Pancreatic eligibility wording from the registry: "Histologically or cytologically confirmed resected pancreatic ductal adenocarcinoma (PDAC), resectable evaluation is based on criteria of NCCN guidelines, no evidence of distant metastasis as demonstrated by imaging;". Sites: China. No results are recorded here; the registry entry is the source.
Shares Nimotuzumab, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nimotuzumab, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Nimotuzumab, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nimotuzumab, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nimotuzumab, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.